Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer

Seminars in Oncology

Volumn 31, Issue 2 SUPPL. 5, 2004, Pages 37-44

  Yardley, Denise A ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; GEMCITABINE; GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 2442648927     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.03.026     Document Type: Article

References (30)

1. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 17:2341-2354, 1999
2. Spiridonidis CH, Laufman LR, Jones J, et al: Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 16:3866-3873, 1998
3. Rischin D, Boyer M, Smith J, et al: A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Ann Oncol 11:421-426, 2000
4. Laufman L, Spiridonidis C, Pritchard J, et al: Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial. Ann Oncol 12:1259-1264, 2001
5. Palmeri S, Vaglica M, Accurso V, et al: Weekly docetaxel (doc) + gemcitabine (gem) as first line therapy for advanced breast cancer (ABC): A multicenter phase II trial. Proc Am Soc Clin Oncol 21:45b, 2002 (abstr 1991)
6. Fountzilas G, Nikolaides C, Bafaloukos D, et al: Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic Cooperative Oncology Group phase II study. Cancer Invest 18:503-509, 2000
7. Mavroudis D, Malamos N, Alexopoulos A, et al: Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10:211-215, 1999
8. Brandi M, Giotta F, Vici P, et al: Salvage chemotherapy with docetaxel (TXT) and gemcitabine (GEM) in metastatic breast cancer (MBC): Preliminary results of a multicenter phase II trial of GOIM (Gruppo Oncologico dell'talia Meridionale). Proc Am Soc Clin Oncol 20:52b, 2001 (abstr 1956)
9. Eckardt JR, Schmidt AM, Needles BM, et al: A phase I study of the combination of docetaxel (G) and gemcitabine (G). Proc Am Soc Clin Oncol 17:920, 1998 (abstr 920)
10. Rigas JR, Rothenberg ML, David TH, et al: Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules. Proc Am Soc Clin Oncol 18:226a, 1999 (abstr 870)
11. Denes AE, Needles BM, Schmidt A, et al: A comparison of two schedules of docetaxel (D) in combination with gemcitabine (G) given every other week. Proc Am Soc Clin Oncol 19:212a, 2000 (abstr 828)
12. Pelegri A, Calvo L, Mayordomo J, et al: Gemcitabine and docetaxel given every 2 weeks as first-line therapy for metastatic breast cancer: Results of a GEICAM phase II study. Proc Am Soc Clin Oncol 21:35b, 2002 (abstr 1950)
13. Kornek G, Haider K, Kwasny W, et al: Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8:1051-1056, 2002
14. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
15. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
16. Estevéz LG, Cuevas JM, Antón A, et al: Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 9:686-692, 2003
17. Perez-Manga G, Lluch A, Alba D, et al: Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial. J Clin Oncol 18:2545-2552, 2000
18. Fumoleau P, Viens P, Dieras V, et al: Final results of gemcitabine and epirubicin phase II trial in metastatic breast cancer patients. San Antonio Breast Cancer Symposium, San Antonio, TX, 2002 (abstr 334)
19. Fumoleau P, Viens P, Dieras V, et al: Gemzar and epirubicin in patients with metastatic breast cancer: Final results of a phase I dose finding study. Eur J Cancer 35:A1173, 1999 (abstr)
20. Luftner D, Flath B, Akrivakis C, et al: Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: Results of a phase I study. Invest New Drugs 16:141-146, 1998
21. Silva A, Gonzalez H, Perez M, et al: Neoadjuvant gemcitabine plus epirubicin in locally advanced breast cancer: Evidence of activity in a phase II study. Proc Am Soc Clin Oncol 21:51b, 2002 (abstr 2015)
22. Gomez H, Kahatt C, Flacon S, et al: A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIb breast cancer. Proc Am Soc Clin Oncol 20:41b, 2001 (abstr 1910)
23. Rivera E, Valero V, Arun B, et al: Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21:3249-54, 2003
24. Rivera E, Valero V, Syrewicz L, et al: Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19:1716-1722, 2001
25. Wong Z-W, Khoo K-S, Shah VA, et al: Phase I/II study of pegylated liposomal doxorubicin (PLD) and gemcitabine (G) as first-line therapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:49b, 2002 (abstr 2008)
26. Conte PF, Bengala C, Danesi R, et al: Gemcitabine, epirubicin and paclitaxel (GET) in metastatic breast cancer (MBC): Preliminary report of a phase I/II study with pharmacokinetic and peripheral blood progenitor cell. (PBPC) mobilization assessment. Proc Am Soc Clin Oncol 17:134a, 1998 (abstr 511)
27. Conte PF, Gennari A, Donati S, et al: Gemcitabine plus epirubicin plus Taxol (GET) in advanced breast cancer: A phase 11 study. Breast Cancer Res Treat 68:171-179, 2001
28. Hamm J, Wilson J, Limbers BC, et al. Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET). Preliminary results from a multicenter phase II trial in inflammatory and locally advanced breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003 (abstr 235)
29. Yardley DA, Whitworth P, Greco FA, et al: Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET). Preliminary results from a multicenter phase II trial in inflammatory and locally advanced breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2003 (abstr 237)
30. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003